MIRASOL: A randomised, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression

  • Richardson, Gary (Primary Chief Investigator (PCI))
  • Lai, Li Hoon (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date30/11/20 → 31/12/24

Keywords

  • Medical oncology
  • Ovarian cancer
  • Clinical trial